Table 1.
Clinico-pathological features of patients with IGF2-high and -low HB in the study cohort (n=31).
| IGF2high (n = 22) |
IGF2low (n = 9) |
p value | |
|---|---|---|---|
|
| |||
| Age (months), median (range) | 17.5 (1–180) | 13 (3–63) | 0.71 |
| >3 years, n (%) | 6 (27%) | 3 (33%) | 1 |
| Gender (male), n (%) | 13 (59%) | 6 (67%) | 1 |
| Serum AFP, ng/mL (range) | 620,000 (341–2,000,000) | 160,000 (663–2,186,461) | 0.27 |
| >1000 ng/ml, n (%) | 20 (95%) | 7 (78%) | 0.21 |
| >1,000,000 ng/ml, n (%) | 5 (23%) | 1 (11%) | 0.64 |
| CHIC* classification (High risk), n (%) | 9 (41%) | 2 (22%) | 0.43 |
| PRETEXT classification | |||
| PRETEXT I | 0 (0%) | 2 (22%) | 0.08 |
| PRETEXT II | 9 (41%) | 2 (22%) | 0.43 |
| PRETEXT III | 8 (36%) | 4 (44%) | 0.70 |
| PRETEXT IV | 5 (23%) | 1 (11%) | 0.64 |
| Neo-adjuvant chemotherapy, n (%) | 21 (95%) | 9 (100%) | 1 |
| Distant metastasis at diagnosis, n (%) | 7 (32%) | 2 (22%) | 0.69 |
| Vascular invasion, n (%) | 10 (45%) | 2 (22%) | 0.42 |
| Multifocality | 10 (45%) | 1 (11%) | 0.11 |
| HCN-NOS $ , n (%) | 2 (9%) | 0 | 1 |
| SCUD # , n (%) | 3 (13%) | 1 (11%) | 1 |
| Tumor histology | |||
| Epithelial, n (%) | 12 (55%) | 3 (33%) | 0.43 |
| Mixed epithelial and mesenchymal, n (%) | 10 (45%) | 6 (97%) | 0.43 |
| Main Epithelial Component | |||
| Fetal, n (%) | 8/22 (36%) | 5 (56%) | 0.43 |
| Non-Fetal, n (%) | 9/22 (41%) | 1 (11%) | 0.20 |
*
CHIC, Children’s Hepatic Tumors International Collaboration-Hepatoblastoma Stratification (CHIC-HS).
$
HCN-NOS: Hepatocellular Malignant Neoplasm, Not Otherwise Specified.
#
SCUD: Small cell undifferentiated hepatoblastoma.